Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Codependent with PBAC- intravesical injection of botulinum toxin (Botox) into the bladder wall for urinary incontinence due to idiopathic overactive bladder. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1272. 2013 Authors' conclusions MSAC supported public funding via the proposed MBS item with the wording of the item descriptor and timing of implementation coordinated with the PBS listing of botulinum toxin type A.
Draft new MBS item Category 3 – Group T11 – botulinum toxin injections
New item 18379
Botulinum toxin type A (Botox), intravesical injection of, with cystoscopy, for the treatment of urinary incontinence, including all such injections on any one day, if:
(a) the urinary incontinence is due to idiopathic overactive bladder in a patient:
(i) who is at least 18 years of age; and
(ii) the patient has urinary incontinence that has been inadequately controlled by at least two alternative anti-cholinergic agents, as manifested by having experienced at least 14 episodes of urinary incontinence per week before commencement of treatment with botulinum toxin type A; and
(b) the patient is willing and able to self-catheterise; and
(c) the requirements relating to botulinum toxin type A under the Pharmaceutical Benefits Scheme are complied with; and
(d) treatment is not provided on the same occasion as a service described in item 104, 105, 110, 116, 119, 11900 or 11919
For each patient—applicable not more than once, except if the patient achieves at least a 50% reduction in urinary incontinence episodes from baseline at any time during the period of 6 to 12 weeks after first treatment
(Anaes.) (H)
MBS fee: $229.85* Benefit: 75% = $172.40
*MBS fee and benefit (rebate) are at the 1 November 2012 rate. Fee and benefit from 1 November 2014 will be
at the 1 July 2014 indexed rate (e.g. $234.00 and $175.50 respectively).
MSAC noted that the flow-on implications for MBS costs were large and highly uncertain and supported the Department undertaking further work to refine these estimates. Indexing Status Subject indexing assigned by CRD MeSH Botulinum Toxins, Type As; Urinary Bladder, Overactive; Urinary Incontinence Language Published English Country of organisation Australia English summary An English language summary is available. Address for correspondence MDP 106, GPO Box 9848, Canberra ACT 2601 AUSTRALIA Email: msac.secretariat@health.gov.au AccessionNumber 32015000434 Date abstract record published 07/04/2015 |